Doxorubicin (DOX) is an effective drug for the treatment of solid tumors and hematological malignancies in both children and adults. The most serious side effect is doxorubicin-induced cardiotoxicity (DIC), which can lead to cardiomyopathy and irreversible and highly fatal cardiac decompensation. The precise mechanisms underlying DIC are not fully understood, and currently, no fully effective preventive or therapeutic strategies exist. Drug repositioning has emerged as a promising approach to mitigate DIC, leveraging existing safety profiles while potentially reducing the time and cost of clinical translation. In this review, we summarize current evidence on drug repurposing for DIC, with a particular focus on the antidepressant paroxetine, which shows potential cardioprotective effects beyond its established role as a selective serotonin reuptake inhibitor (SSRI).
Cardiomyopathies represent a heterogeneous group of diseases that lead to functional and structural impairment of the myocardium, frequently culminating in heart failure. Due to ethical and technical constraints inherent to human studies, rat models have become indispensable in experimental cardiology. Transthoracic echocardiography represents one of the most commonly used methods for assessing cardiac structure and function in experimental rat models of cardiomyopathy, due to its accessibility, non-invasiveness, ease of use, safety and cost-effectiveness. Almost all echocardiographic examinations in rats require a certain level of pharmacological sedation or general anesthesia to immobilize the animal and reduce motion-induced artifacts. A review of the literature reveals that only a few anesthetics are used in experimental practice. By far the two most prevalent choices are isoflurane and the ketamine-xylazine combination. Less frequently used are pentobarbital, the tiletamine-zolazepam combination, sevoflurane, and acepromazine. However, the interpretation of echocardiographic findings in experimental animals can be significantly biased by the effects of anesthesia primarily on the autonomic nervous system and cardiac contractility. Therefore the choice of anesthetic or sedative protocol represents an important, yet insufficiently standardized, methodological variable in the echocardiographic assessment of rat models of cardiomyopathy. Here we discuss the bias introduced by the use of sedatives/anesthetics when performing echocardiography in different rat models of experimental cardiomyopathy.
Cardiovascular system (CVS) adaptation during pregnancy involves numerous hemodynamic changes and remodeling of peripheral and central regulatory mechanisms. A decrease in blood pressure (BP) during pregnancy activates the baroreflex, leading to an increase in sympathetic tone and the synthesis and secretion of vasopressin (VP). It is well-established that VP plays a critical role in the adaptation to normotensive pregnancy, as well as in the development of primary hypertension. However, the effects of VP on neuroendocrine and autonomic adaptation of the CVS in the context of chronic hypertension during pregnancy remain insufficiently studied. This study was conducted on normotensive Wistar (WR) and spontaneously hypertensive rats (SHR) implanted with radiotelemetry devices for continuous hemodynamic measurements. BP and heart rate (HR) variability were assessed through spectral analysis, while baroreflex sensitivity (BRS) was measured using the sequence method. Plasma VP concentration was measured by ELISA, and gene expression of VP, V1aR, and V1bR was analyzed via RT-qPCR. The results indicate that non-pregnant SHR females exhibit higher gene expression of VP, V1aR, and V1bR in the paraventricular nucleus (PVN) and supraoptic nucleus (SON) compared to WR females in diestrus. Pregnant SHR females show reduced VP expression in the SON, lower plasma VP concentrations, and normalized BP during late pregnancy, but also exhibit signs of increased sympathetic cardiac stimulation (elevated HR and LF-HR), as well as activation of vagal mechanisms (increased BRS and HF-HR). In WR females, late pregnancy induces increased gene expression of VP in the PVN and SON, while changes in plasma VP levels and BP are less pronounced, as are alterations in autonomic control. These findings indicate differences in adaptation between WR and SHR females.
Introduction: Bones are fundamental components of the skeletal system that undergo continuous remodeling throughout life. Osteoclasts are responsible for bone resorption, while osteoblasts form new bone matrix and indirectly influence osteoclast differentiation through signaling pathways involving molecules such as M-CSF, c-Fms, GRB2, ERK, PI3K, and Akt. To maintain bone health, increasing attention is being given to nutritional interventions, including the Mediterranean diet, which is rich in bioactive compounds. The aim of this study was to perform an in silico analysis of potential interactions between the most prevalent bioactive compounds of the Mediterranean diet and the key proteins of the osteoclast differentiation signaling pathway. Materials and Methods: A library comprising 115 predominant bioactive compounds from the Mediterranean diet was constructed based on literature data. Protein structures obtained via crystallography were used as targets in molecular docking simulations to predict interactions between ligands and receptors. Results: Most ligands did not show significant interactions with the investigated proteins (ΔG > -7 kcal/mol), except in the case of Akt protein. For this protein, a larger number of ligands demonstrated ΔG values < -7 kcal/mol. The five most potent ligands (salvianolic acid, apigenin, diosmin, mangiferin and sylbin) bound to amino acid sequences forming the active site of the receptor, indicating a potential inhibitory effect. Conclusion: The in silico analysis suggests that bioactive components of the Mediterranean diet possess potential to inhibit Akt protein (protein kinase B), thereby opening new perspectives for their application in modulating osteoclast activity and developing novel strategies for maintaining bone health.